Apr. 16, 2014, 5:30 PM
Apr. 16, 2014, 9:28 AM
- Baxter International's (BAX) BAX 111 treatment met the primary endpoint in a Phase III trial of patients with von Willebrand disease, the most common type of inherited bleeding disorder.
- BAX 111 successfully treated 22 patients who experienced bleeding episodes during the trial.
- Secondary endpoints included those related to additional efficacy and safety measures, pharmacokinetics and health-related quality of life.
- Shares are +1.55% premarket. (PR)
Mar. 27, 2014, 9:11 AM
Mar. 27, 2014, 8:08 AM
- Baxter International (BAX) is splitting into two companies, with one focused on biopharmaceuticals and the other on medical products.
- Baxter will make a tax-free distribution of shares in the biopharmaceuticals business to its shareholders. The company expects to complete the transaction by mid-2015.
- The biopharmaceuticals business generated 2013 annual revenues of $6B and develops treatments for hemophilia and other bleeding disorders, immune deficiencies, burns and shock.
- The medical-products business earned annual sales of over $9B and provides intravenous (IV) solutions and nutritional therapies, drug-delivery systems and administration sets, and premixed and other injectable drugs, as well as inhalation anesthetics and hospital-based biosurgery products.
- Baxter CEO Robert Parkinson will head the medical-products company, which will retain the Baxter International name.
- Ludwig Hantson, who is president of BioScience, will run the biopharmaceuticals firm. (PR)
- Shares are +12.5%.
Mar. 26, 2014, 12:27 PM
Mar. 26, 2014, 8:33 AM
- Large cap pharma and biotech firms have regenerative therapy R&D programs underway according to a recent survey.
- 69% of respondents are focused on developing cellular-based therapies.
- Wound healing and burns have the greatest near-term potential.
- Long term areas of interest are cardiovascular disease, oncology, neurodegenerative disease, monogenic disorders and ocular disease.
- (AGN) (AMGN) (BAX) (BIIB) (CELG) (LLY) (GSK) (JNJ) (NVS) (NVO) (PFE) (RHHBY) (SNY) (MRK) (SHPG)
Mar. 17, 2014, 10:23 AM
- Goldman Sachs removes Baxter International (BAX) from its Conviction List and lowers its PT from $83 to $77 but maintains its Buy recommendation. Since the firm added BAX to its Americas CL in August it is off 7.7% versus the S&P 500's 8.5% gain.
- Analyst David Roman cites a higher risk profile due to heightened competition in the plasma business.
- Investors appear unconcerned. Shares are up a fraction in early trading.
Mar. 4, 2014, 4:49 PM
- Cell Therapeutics (CTIC) Q4 revenue balloons to $32.9M versus $0 a year ago. Almost all of the revenue is due to Baxter's (BAX) upfront payment of $32.4M for the license to develop and commercialize pacritinib.
- Product revenues for Q4 and FY13 were $.5M and $2.3M, respectively.
- Net income for the quarter was $10.2M ($.08/share) due to the Baxter payment. Net loss for the year was $49.6M ($.43/share).
- FY14 guidance projects a loss from operations of $45M - $50M.
- Consensus estimate for Q1 is a loss of $.23/share on revenues of $1.3M.
- Consensus estimate for 2014 is a loss of $.48/share on revenues of $23.9M.
- Mutual fund ownership has increased from 30 to 85 the past 4 quarters.
Feb. 18, 2014, 9:28 AM
Jan. 23, 2014, 8:45 AM
- Baxter (BAX) net profit -34% to $326M, hurt by expenses related to its $4B acquisition of Swedish dialysis product manufacturer Gambro, collaborations and other items.
- Gross margin dropped to 44.7% from 50.8%
- Sales breakdown: medical products +25% to $2.59B, including $413M from Gambro. Bioscience +5% to $1.78B, mainly boosted by solid demand for Baxter's hemophilia treatments.
- Guidance: Q1 adjusted EPS $1.06-1.09 vs consensus of $1.14; 2014 EPS $5.05-5.25 vs $5. (PR)
Jan. 23, 2014, 7:02 AM| Comment!
Jan. 23, 2014, 12:05 AM
Jan. 22, 2014, 5:30 PM
Jan. 7, 2014, 9:25 AM
Dec. 19, 2013, 3:44 PM
- Baxter (BAX -0.5%) gets another indication for the hemophilia treatment FEIBA.
- The FDA has approved the drug for the prophylactic treatment of patients with hemophilia A or B who have developed inhibitors.
- "This additional indication ... is aimed at reducing the number of bleeds among this patient population," the company's president of BioScience says. (PR)
Nov. 18, 2013, 3:12 PM
- Perhaps not surprisingly, Credit Suisse's Baxter (BAX +0.1%) upgrade is in part attributable to the expected three-month delay in FDA approval for Biogen's (BIIB -2.1%) long-lasting factor VIII therapy Eloctate.
- Concerns about looming competition in the hemophilia market have been a thorn in BAX's side over the past several months.
- In hiking his price target to $80 from $73, analyst Bruce Nudell also highlights "BAX's recent enrollment of its own long-acting rFVIII trial" (BAX 855) and points to "the potential for value creation should BAX split its Medical Products & Bioscience segment."
BAX vs. ETF Alternatives
Baxter International Inc is a healthcare company which develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic.
Other News & PR